Increased phosphorylation of 4E‑binding protein 1 predicts poor prognosis for patients with colorectal cancer.
As demonstrated in previous studies, the phosphorylated form of 4E‑binding protein 1 (p‑4E‑BP1) may be a suitable tumor biomarker. The aim of the current study was to examine the expression status of p‑4E‑BP1 in colorectal cancer (CRC), in order to determine its clinical significance. The present study enrolled 89 patients with CRC that had undergone radical resection. Paired tumor and adjacent normal tissues were evaluated using immunohistochemistry to detect the protein expression of p‑4E‑BP1 and phosphatase and tensin homolog (PTEN). The study identified 53 cases (59.6%) that exhibited moderate or high expression of p‑4E‑BP1 in tumor tissues, compared with little or no expression in the adjacent normal tissues. Conversely, PTEN protein expression was markedly lower in CRC compared with adjacent normal tissues. p‑4E‑BP1 protein upregulation tissues samples was consistent with PTEN downregulation in CRC samples. p‑4E‑BP1 overexpression was predominant in patients with metastasis to the regional lymph nodes. Moderate/high expression of p‑4E‑BP1 protein was significantly associated with adverse overall survival (OS) in patients. Statistical analysis using the Cox proportional hazards model, indicated that p‑4E‑BP1 expression was an independent factor suitable for predicting OS in CRC patients, which was independent of lymph node metastasis. In conclusion, p‑4E‑BP1 protein expression appears to be upregulated in CRC, suggesting that it may be a suitable biomarker for predicting CRC prognosis.
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.
Yufeng
Y
Miao
Department of Pharmacy, Yancheng First People's Hospital, Yancheng, Jiangsu 224001, P.R. China.
Lige
L
Chen
Department of Hepatology, Yancheng No. 2 People's Hospital, Yancheng, Jiangsu 224002, P.R. China.
Cuifen
C
Shi
Department of General Surgery, Yancheng First People's Hospital, Yancheng, Jiangsu 224001, P.R. China.
Rengen
R
Fan
Department of Medical Oncology, Yancheng First People's Hospital, Yancheng, Jiangsu 224001, P.R. China.
Ping
P
Chen
Department of Medical Oncology, Yancheng First People's Hospital, Yancheng, Jiangsu 224001, P.R. China.
Hongqi
H
Liu
Department of Clinical Laboratory, Yancheng First People's Hospital, Yancheng, Jiangsu 224001, P.R. China.
Aihua
A
Xia
Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China.
Haixin
H
Qian
D048868:Adaptor Proteins, Signal Transducing / Q000378:metabolism*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D018797:Cell Cycle Proteins; D015179:Colorectal Neoplasms / Q000378:metabolism* / Q000473:pathology; D015536:Down-Regulation; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D051059:PTEN Phosphohydrolase / Q000378:metabolism; D010750:Phosphoproteins / Q000378:metabolism*; D010744:Phosphoric Monoester Hydrolases / Q000378:metabolism; D010766:Phosphorylation; D011379:Prognosis; D015854:Up-Regulation
D048868:Adaptor Proteins, Signal Transducing; D014408:Biomarkers, Tumor; D018797:Cell Cycle Proteins; C087000:EIF4EBP1 protein, human; D010750:Phosphoproteins; D010744:Phosphoric Monoester Hydrolases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human